Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Epinastine Hydrochloride

FDA-approved product (solution/drops, ophthalmic), marketed as Elestat, Epinastine Hydrochloride.

Registered studies
10
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Epinastine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic disease
  • Eye allergy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antihistamines for systemic use; Other antiallergics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Epinastine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Epinastine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients

    NCT06212973 · start 2023-03-13

    Registered record
    Registry ID
    NCT06212973
    Conditions
    Seasonal Allergic Conjunctivitis
    Interventions
    Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln; Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-03-13
    Completion
    2023-11-02
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Conjunctivitis
    InterventionEpinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln; Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan

    NCT02251613 · start 2013-12

    Registered record
    Registry ID
    NCT02251613
    Conditions
    Allergic Conjunctivitis
    Interventions
    Olopatadine HCl ophthalmic solution, 0.1%; Epinastine HCl ophthalmic solution, 0.05%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionOlopatadine HCl ophthalmic solution, 0.1%; Epinastine HCl ophthalmic solution, 0.05%
    PhasePhase 4
    Registry statusCompleted

  • Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis

    NCT01569191 · start 2012-03

    Registered record
    Registry ID
    NCT01569191
    Conditions
    Hypersensitivity
    Interventions
    Artificial Tear Supplement; Cold compress; Anti-allergic Medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypersensitivity
    InterventionArtificial Tear Supplement; Cold compress; Anti-allergic Medication
    PhasePhase 4
    Registry statusCompleted

  • Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

    NCT00534794 · start 2007-10

    Registered record
    Registry ID
    NCT00534794
    Conditions
    Allergic Conjunctivitis
    Interventions
    Elestat; Pataday
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-10
    Completion
    Not recorded
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionElestat; Pataday
    PhasePhase 4
    Registry statusCompleted

  • Comparison of CL Wear Between Two Allergy Drops

    NCT00489398 · start 2007-07

    Registered record
    Registry ID
    NCT00489398
    Conditions
    Allergic Conjunctivitis
    Interventions
    epinastine HCL and olopatadine HCL
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2007-07
    Completion
    2008-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    Interventionepinastine HCL and olopatadine HCL
    PhasePhase 4
    Registry statusWithdrawn

  • Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria

    NCT02238249 · start 2005-10

    Registered record
    Registry ID
    NCT02238249
    Conditions
    Urticaria
    Interventions
    Alesion®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-10
    Completion
    Not recorded
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrticaria
    InterventionAlesion®
    PhaseNot recorded
    Registry statusCompleted

  • Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus

    NCT02238236 · start 2005-05

    Registered record
    Registry ID
    NCT02238236
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Alesion®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-05
    Completion
    Not recorded
    Enrolment
    3,793

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionAlesion®
    PhaseNot recorded
    Registry statusCompleted

  • Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet

    NCT02238223 · start 2004-04

    Registered record
    Registry ID
    NCT02238223
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Alesion®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-04
    Completion
    Not recorded
    Enrolment
    2,001

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionAlesion®
    PhaseNot recorded
    Registry statusCompleted

  • WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis

    NCT02182544 · start 2001-06

    Registered record
    Registry ID
    NCT02182544
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    WAL801CL dry syrup; Ketotifen fumarate dry syrup; Ketotifen fumarate dry syrup placebo; WAL 801 CL dry syrup placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-06
    Completion
    Not recorded
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionWAL801CL dry syrup; Ketotifen fumarate dry syrup; Ketotifen fumarate dry syrup placebo; WAL 801 CL dry syrup placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

    NCT01363700

    Registered record
    Registry ID
    NCT01363700
    Conditions
    Allergic Conjunctivitis
    Interventions
    DE-114 ophthalmic solution; Placebo ophthalmic solution; Olopatadine Hydrochloride 0.1% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionDE-114 ophthalmic solution; Placebo ophthalmic solution; Olopatadine Hydrochloride 0.1% Ophthalmic Solution
    PhasePhase 3
    Registry statusCompleted